Syncom Formulations (India) Ltd. — Interim / Quarterly Report 2023

Feb 13, 2023

Syncom Formulations (lndia) Limited

A WHO-GMP & lS0 9001-2015 Cerlified Company CIN No. : 124239MH1988P1C047759

SYNCOM/SEI2O22-23 l3tn Februa ry,2023

Online fi ling at: www.listing.bsein(_ia,cgp and http ^s: //ne ap s. n se i nd i a. c o m,N E W L I S T IN G C O RP/ I o g i ⁿj sp

To. BSE Limited Ph iroze Jeejeebhoy Tower, Dalal Street, Mumbai (M.ll.) 400 ⁰⁰¹ BSE CODE:524470

To, National Stock Exchange of India Limited Erchange Plaza, C-1, Block G, Bandra Kurla Complex, Bandra (E), \lumbai- 400051 \SE SYMBOL: SYNCOMF

Subject: Submission of the Un-Audited Standalone and Consolidated Financial Results along with Limited Review Report thereon for the Quarter and Nine Months ended 3l't December, 2022 as per Regulation 33(3)(d) of SEBI (LODR) Regulations,20t5.

Dear Sir/Ma'am,

This is in continuation of our letter no. SYNCOMISE1}O22-23 dated 2"dFebruary. 2023 regarding intimation of Board nteetins tbr consideration and approval of Standalone and Consolidated Un-Audited Financial Results tbr the Quarterand Nine Months ended 3l't December,2022.

Pursuant to Regulation 33 of SEBI (LODR) Regulatiorrs. 2015. we are pleased to the following:

• L Standalone and Consolidated Unaudited Financial Results of the Cornpany for the Quarler and Nine Nlonths ended on 31" December.2022;
• 1. Standalone artd Consolidated Linrited Review Reporl by the Statutory Auditors of the colnpan\ for the Quarter and Nine Montlrs ended on 3 l'' Decemb er.2022.

which was considered and approved by the Board at their 712022-23 Meeting held on Monday, the ^I3'r' February ,2023.

The meeting of the Board of Directors commerrced at 4:00 P.M. and conclLrded at 8:00 P.M,

We are also in process to file the aforesaid financial results in XBRL format within the stipLrlated tirne and same shall als: be hosted at the website of the company www,qfi!,in.

The Financial Results will also be published in widely circulated English & Marathi (Vernacular) newspaper in the prescribed forrnat for that purpose.

You are requested to take on record the above said Standalone and Consolidated Un-Audited Financial Resultsalong with Limited Review Repoft for your reference and record.

Thanking You, Yours Faithfully, For, SYNCOM FORMULATIONS (INDIA) LIMITED

Prachi Jain Digitally signed by Prachi Jain DN: c=IN, o=Personal, 2.5.4.20=a9c7f2c99a11944b44d0942c 6cf605932c51ac494a63e536b5695c8b c14d9123, postalCode=452001, st=Madhya Pradesh, serialNumber=2ab15a1b9a74884d7a1 8c23afdbfb7b1eb11643306081e9406 a55dbbe8037f74, cn=Prachi Jain Date: 2023.02.13 20:12:23 +05'30'

CS PRACHI JAIN COMPANY SECRBTARY & COMPLIANCE OFFICER

Ettcl: Standalone ond Cr 'inoncial Results und Limited Review Report.

d O*roc/e o?c ec?ltre ldce.,,

Regd. Off. Fax : +9 1 -022-30887755 Email : stil87 @ hotmail.com

Corp.Off.

Works

Website

SANJAY MEHTA & ASSOCIATES

Ch artered Accountants

Limited Review Report on Un-audited Standalone Financial Results for the Quarter &Nine Month ended 31't December,2022 pursuant to Regulation 33 of the SEBI(LODR) Regulations, 2015

To, The Board of Directors of SYNCOM FORMULATIOI{S (INDIA) LIMITED Indore (M.P.)

• 1. We have reviewed the accompanying statement of Standalone Unaudited Financial Results of SYNCOM FORMULATIONS (INDIA) LIMITED ("the compsny"), for the period ended Decembet, 31, 2022 ("the Statement"), attached herewith, being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (LODR) Regulations, 2075, as amended including relevant circular issued by the SEBI from time to time.
• This statement which is the responsibility of the Company's Management and has been approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 Interim Financial Reporting" ("IND AS 34"), prescribed under Section 133 of the Companies Act, 2013, as amended read with relevant rules issued thereunder and other Accounting principles generally accepted in India and in compliance with the Regulation 33 of the SEBI (LODR) Regulations, 2015, as amended, including relevant circulars issued by the SEBI from time to time. Our responsibility is to issue a report on these Financial Statements based on our review. 2.
• We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, 'oReview of Interim Financial Information performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the hnancial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion. J.
• Based on our review conducted as stated above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with applicable Accounting Standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015,including the manner in which it is to be disclosed, or that it contains any material misstatement. 4.

Place: Indore Date: l3thFebruary, 2023

For, Sanjay Chartered FRN:011 ta &Associates

CA Manish Mittal (Partner) M.No.079452 UDIN: 2307 9452BGQXSZ85 ¹1

SYNCOM FORMULATIONS (INDIA) LIMITED

Regd.Off :- 7, Niraj Industrial Estate, Off Mahakali Caves Road, Andheri (E) Mumbai-400093

Works:- 256-257, Sector - 1, Pithampur, Dist: Dhar-454775

E Mail:- finance@sfil.in, Website:- www.sfil.in, CIN :- L24239MH1988PLC047759

STANDALONE UNAUDITED FINANCIAL RESULTS FOR THE QUARTER/NINE MONTHS ENDED 31ST DECEMBER, 2022

							(Rs.In Lakhs) (Except EPS)
S. No.	Particulars	Quarter Ended			Nine months ended		Year Ended
		31-12-2022	30-09-2022	31-12-2021	31-12-2022	31-12-2021	31-03-2022
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
$\mathbf{1}$	Revenue from Operations	5738.29	5449.14	5722.60	16327.47	16143.23	21966.32
$\overline{2}$	Other Income	197.85	287.19	223.54	783.01	629.08	1199.25
$\overline{3}$	Total Income $(1 + 2)$	5936.14	5736.33	5946.14	17110.48	16772.31	23165.57
$\overline{4}$	EXPENSES
	a) Cost of materials consumed	2199.90	2888.04	3123.61	7391.22	7454.76	9741.23
	b) Purchases of Stock-in-Trade	1094.05	978.87	1234.36	2939.98	3146.52	3981.41
	(c) Changes in inventories of finished goods, Stock-in-Trade and work-in-progress	183.32	(233.88)	(554.08)	101.52	(256.67)	331.62
	(d) Employee benefits expense	725.67	643.26	598.53	1866.79	1605.17	2215.78
	(e) Finance costs	71.70	61.76	15.39	183.83	46.26	135.52
	(f) Depreciation and amortization expense	120.15	117.50	99.20	337.15	293.68	394.84
	(g) Other expenses	944.79	743.84	830.24	2660.42	2436.65	3749.99
	Total expenses (4)	5339.58	5199.39	5347.25	15480.91	14726.37	20550.39
5	Profit/(loss) before exceptional items and tax (3-4)	596.56	536.94	598.89	1629.57	2045.94	2615.18
6	Exceptional Items	0.00	0.00	0.00	0.00	3.48	2.41
$7\phantom{.}$	Profit/(loss) before tax (5 - 6)	596.56	536.94	598.89	1629.57	2049.42	2617.59
8	Tax expense:
	(1) Current tax	161.00	142.00	173.17	406.00	521.17	624.58
	(2) Deferred tax	21.05	35.10	24.41	63.15	24.98	13.97
9	Profit (Loss) for the period from continuing operations (7-8)	414.51	359.84	401.31	1160.42	1503.27	1979.04
10	Profit/(loss) from discontinued operations	0.00	0.00	0.00	0.00	0.00	0.00
11	Tax expense of discontinued operations	0.00	0.00	0.00	0.00	0.00	0.00
12	Profit/(loss) from Discontinued operations (after tax) (10-11)	0.00	0.00	0.00	0.00	0.00	0.00
13	Profit/(loss) for the period $(9 + 12)$	414.51	359.84	401.31	1160.42	1503.27	1979.04
14	Other Comprehensive Income
	A(i) Items that will not be reclassified to profit or loss	0.00	0.00	0.00	0.00	0.00	0.00
	(ii) Income tax relating to items that will not be reclassified to
	profit or loss	0.00	0.00	0.00	0.00	0.00	0.00
	$B(i)$ items that will be reclassified to profit or loss	111.57	121.30	174.85	147.51	197.17	121.70
	(ii) Income tax relating to items that will be reclassified to profit or loss	0.00	0.00	0.00	0.00	0.00	0.00
15	Total Comprehensive Income for the period (XIII+XIV)
	(Comprising Profit (Loss) and Other Comprehensive
	Income for the period)	526.08	481.14	576.16	1307.93	1700.44	2100.74
16	Paid up Share Capital of the Company (Face Value 1/-)	9400.00	9400.00	8299.53	9400.00	8299.53	8624.53
17	Reserves excluding revaluation reserves						13597.63
18	Earnings per equity share (for continuing operation):
	$(1)$ Basic	0.06	0.06	0.07	0.14	0.21	0.26
19	(2) Diluted Earnings per equity share (for discontinued operation):	0.06	0.06	0.06	0.14	0.19	0.24
	$(1)$ Basic
	(2) Diluted	0.00 0.00	0.00 0.00	0.00 0.00	0.00 0.00	0.00 0.00	0.00 0.00
20	Earnings per equity share (for discontinued & continuing
	operations)
	$(1)$ Basic (2) Diluted	0.06 0.06	0.06 0.06	0.07 0.06	0.14 0.14	0.20 0.19	0.26 0.24

Place: Indore

Date: 13/02/2023

SYNCOM FORMULATTONS (tNDtA) LtMtTED

Regd.Off :- T,Niraj lndustrial Estate,Off l\,lahakali Caves Road,Andheri (E) Mumbai-400093

Works:- 256-257, Sector- 1, Pithampur, Dist: Dhar-454775

E Mail:- finance@sfil.in, Website:- M.sfil.in, CIN :- L24239MH1988PLC047759

STANOALONE UNAUDITED FINANCIAL RESULTS FOR THE QUARTERYNINE MONTHS ENDED 31ST DECEMBER,2022

	Pa rtic u lars		Quarter Ended		Nine months ended	Year Ended
S. No.		31-12-m22	30-09-m22	31-12-m21	31-12-m22	31 -12-2021	31-03-2022
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
,	Segment R€venue
	a) Pharmaceuticals Drugs & Fcrmulabons	4615.r13	5644.39	5520.21	15105.6i	16006.7{	21954.6t
	b) Trading of Commodilies	1237.X	1.13	353.53	1749.3{	570.81	942.34
	c) Renting of Property	83.1 C	90.51	72.37	255.4-t	'194.0t	268.54
	Total Segment Rovenue	5936.'r 4	5736.33	5946.14	17110.4t	16772.3	23165.56
	Less: !nter Segment Revenue		0.0c	0.0r		0.0(	0.0€
	Revenu€ from Operations	5936.1 {	5736.33	5946.'l	171',10.4t	16772.3	231 65.56
2	Segment Results Profit(+)/Loss(-) before tax
	and interest from each segment
	a) Pharmaceuticals Drugs & Formulations	583.94	507.8i	535.31	1 538.7{	1 869.9t	2427.82
	b) Trading of Commodities	'1.'16	0.32	6.60	19.1t	27.5!	56.7A
	c) Renting of Property	83.1 6	90.51	72.37	255.41	194.6t	268.5€
	Total Profit before tax	668.26	598.7(	614.28	1813.4(	2092.2	27 53.1
	Less: i) lnterest	71.7C	61 ,7(	15.3€	183.8i	46.2	135.5i
	ii) Other Un-allocable Expenditure	0.0c	0.0(		0.0(	3.4t	0.0(
	Profit before tax	596.5(	536.9r	598.8{	1 629.57	2049.42	26',t7.51
	(Segment Asset-Segm€nt Liabilities)
	Segment Asset
	a) Pharmaceuticals Drugs & Formulations	33163.2t	32915.2t	28864.0t	331 63.2€	28864.08	25600.8t
	b) Trading of Commodities	0.0(	0.0(	157.8i	0.0c	157.82	483.7i
	c) Renting of Property	4733.4!	4753.6t	4713.3t	4733.45	4713.34	4739.2'
	Total Segment Asset	37896.71	37668.9:	33735.21	37896.71	33735.24	30823.8:
	Un-allocable Assets					0.0c	0.0(
	Net Sogment Asset	37E96.71	37668.9!	33735.2t	37896.7'l	33735.24	30823.E:
	Segment Liabilities
	a) Pharmaceuticals Orugs & Formulations	13032,4	1 3330.61	7721 .1i	13032.44	7721.12	8412.31
	b) Trading of Commodities	0.0(	0.0(	93.41	0,0c	93.42	42.6t
	c) Renting of Property	157.75	157.71	4713.31	1qa 1c	4713.34	146.6t
	Total Segment Liabilities	1 31 90.2i	1 3486.3I	12527.8t	1 31 90.2i	12527.E8	8601 .67
	Un-allocable Liabilities						0.0(
	Net Segment Liabilities	't 3't 90.2i	1 3488.3t	12527.8t	1 31 90.2:	12527.88	8601.6?

Notes:-

1 The above resulls were reviewed by the Audit Committee and approved by the Board at its meeting held on lglo2ti )nra

2 These above results have been prepared in compliance with the lndian Accounting Standard (referred to as "lnd AS Companies Act, 2013 read with Companies (lndian Accounling Standards) Rules 2015 as amended from time to tin )") as notified prescribe ne. d under Section 133 of the

3 The company is operating in 3 segments i.e. (a) Pharmaceuticals Drugs & Formulations (b) Trading of Commoditie! results are given as required. s (c) Renting of Properl ly, particulars of segment wise

4 As required under Regulation 33 of SEBI (LODR) Regulations, 2015 the limited review by the Statutory Auditors ha\ December, 2022. fhe report does not have any impact on the above results and notes which needs explanation. /e been completed for ¹ ihe quarter ended on 31st

5 Previous period figures have been regrouped/reclassified wherever necessary to confirm to this period classificatiot 1.

6 The Company has incorporated 3 (three) Wholly Owned Subsidiaries nemely Synmex Pharma Pvt. Ltd. and Sante ^I lntemational hd. Ltd. on 25th Juty, 2022 .The Subsidiary Companies are taking necessary steps to obtain required Authorities-Therefore, during the Quarter under r6view, these Subsidiary Companies were not having any Business 3iolech Pvt. Ltd. on 21! Drug Licenses and oth Activities. n July, 2022 and Vincit Biotech er approvals from the Competent

7 The Company is in the process to commence the commercial production of its new Expansion Plant by th6 first Qur rrter of the Financial Yc >at 2023-24.

8 The company has generated Rs. 1035.76 Lakhs being the upfront amount and Rs, 2995.74 Lakhs by conversion of Rs. 1^ each issued at a premium of Rs. 1.53 per share aggregating Rs. 4031.50 Lakhs. Out of which the company the work is completed and capitalized as well as Rs. 2048.50 Lekhs is utilized towards the continuing ongoing capitr unutilized amount of Rs. 980.50 Lakhs will be used in the subsequent period. There is no deviation in the projeq! till required under regulation 32 being filed to the BSE Ltd. and NSE Ltd. separately. ¹5,93,47,820 warrants has already utilized the rl work in progress, tota 31st Oecember, 2022 to 1 5,93,47,820 equity shares of ' amount of Rs. 1 002.50 Lakhs being rl Rs.3051.00 Lakhs. Remaining and necessary report towards as

9 Government of lndia's Code for Social Security 2020(the 'Code') received assent from the President in September i applicable and the Rules have not yet been notified. Company will assess the impact of the Code and account for tl^ 2020. However, the dat re same once the etfec' e from when the Code will become tive date and rules are notified.

	om Formulations (lndia) Limited
r"Y tI-, zI	Shankarlal Bankda & Wholetime Director DIN: 00023050
"e,L/, N*'oaDZ

Place: lndore

Oatei'1310212023

SANJAY MEHTA & ASSOCIATES

Ch arteredAccountants

Limited Review Report on Un-audited Consolidated Financial Resulti for the Quarter and Nine Months ended 31't December,2022 pursuant to Regulation 33 of the SEBI(LODR) Regulations, 2015

To, The Board of Directors of SYNCOM FORMULATIONS (INDIA) LIMITED Indore (M.P.)

• l. We have reviewed the accompanying statement of ConsolidatedUnaudited Financial Results of SYNCOM FORMULATIONS (INDIA) LIMITED ("the Parent") and its subsidiaries (the parent and its subsidiaries together referred to as "the Group"), for the period ended December, 31, Z02Z ("the Statement"), attached herewith, being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (LODR) Regulations,2OlS, as amindid including relevant circular issued by the SEBI from time to time.
• 1. This statement which is the responsibility of the Company's Management and has been approved by the Company's Board of Directors, has been prepared in accoidance with the recognition ani measurement principles laid down in the Indian Aicounting Standard 34 Ilterim Fi,ancial Reporting" ("lND AS 34"), prescribed under Section 133 of the Cornpanies Act,20l3, and other Accounting principles generally accepted in India and in compliance with the Regulation 33 of the SEBI (LODR) Regulations,2015, as amended, including relevant circulars issued-by the SEBI from time to time. Our responsibiliff is to issue a report on these Financial Statements based on our review.
• We conducted our reviewof the Statement in accordance with the Standard on Review Engagements (SRE) 2410,"Review of Interim Financial Information performed by the Independent Auiitir of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and anall'tical procedures applied to financial data and thus provid" i..s ^.s,,rance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion. a J.

S. No.	Name of the Company	Relationship with the Holding Company
	Sante Biotech Pvt. Ltd.	Wholly Owned Subsidiary
	Synmex Phanna Pvt. Ltd.	Wholly Owned Subsidiary
	Vincit Biotech International Pvt. Ltd,	Wholly Owned Subsidiary

• The Statement includes the results TCSLIIIS of ^O the following \ Ing entiW: 4.
• 1. Based on our review conducted as stated above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with applicable Accounting Standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Li'sting Obligations and Disclosures Requirements) Regulations, 2015,including the manner in which it ls to be disclosed. or that it contains any material misstatement.

Place: Indore Date: l3thFebruary, 2023

For, Sanjay Mehta &Associates
ffi
UDIN: 2307 9452BGQXTA7403

SYNCOM FORMULATIONS (INDIA) LIMITED

Regd.Off :- 7, Niraj Industrial Estate, Off Mahakali Caves Road, Andheri (E) Mumbai-400093

Works:- 256-257, Sector - 1, Pithampur, Dist: Dhar-454775

E Mail:- finance@sfil.in, Website:- www.sfil.in, CIN :- L24239MH1988PLC047759

CONSOLIDATED UNAUDITED FINANCIAL RESULTS FOR THE QUARTER/NINE MONTHS ENDED 31ST DECEMBER , 2022

							Rs. In Lacs
S. No.	Particulars	Quarter Ended			Nine months ended	Previous Year Ended
		31-12-2022	30-09-2022	31-12-2021	31-12-2022	31-12-2021	31-03-2022
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
$\mathbf{1}$	Revenue from Operations	5738.29	5449.14	5722.60	16.327.47	16143.23	21966.32
$\overline{2}$	Other Income	197.85	287.19	223.54	783.01	629.08	1199.25
3	Total Income $(1 + 2)$	5936.14	5736.33	5946.14	17,110.48	16772.31	23165.57
$\overline{4}$	EXPENSES
	a) Cost of materials consumed	2199.90	2888.04	3123.61	7,391.22	7454.76	9741.23
	b) Purchases of Stock-in-Trade	1094.05	978.87	1234.36	2,939.98	3146.52	3981.41
	c) Changes in inventories of finished goods, Stock-in- Trade and work-in-progress	183.32	(233.88)	(554.08)	101.52	(256.67)	331.62
	d) Employee benefits expense	725.67	643.26	598.53	1,866.79	1605.17	2215.78
	e) Finance costs	71.70	61.76	15.39	183.83	46.26	135.52
	(f) Depreciation and amortization expense	120.15	117.50	99.20	337.15
	(g) Other expenses	944.82	744.53	830.24	2,661.13	293.68 2436.65	394.84
	Total expenses (4)	5339.61	5200.08	5347.25			3749.99
5	Profit/(loss) before exceptional items and tax (3-4)				15,481.62	14726.37	20550.39
6	Exceptional Items	596.54	536.25	598.89	1,628.86	2045.94	2615.18
$\overline{7}$	Profit/(loss) before tax (5 - 6)	0.00	0.00	0.00	0.00	3.48	2.41
$\boldsymbol{8}$	Tax expense:	596.54	536.25	598.89	1,628.86	2049.42	2617.59
	(1) Current tax	161.00	142.00	173.17	406.00	521.17	624.58
	(2) Deferred tax	21.05	35.10	24.41	63.15	24.98	13.97
9	Profit (Loss) for the period from continuing	414.49	359.15
10	operations (7-8) Profit/(loss) from discontinued operations	0.00	0.00	401.31 0.00	1,159.71 0.00	1503.27 0.00	1979.04 0.00
11	Tax expense of discontinued operations		0.00	0.00	0.00	0.00	0.00
12	Profit/(loss) from Discontinued operations (after tax) (10-
13	11) Profit/(loss) for the period $(9 + 12)$	0.00	0.00	0.00	0.00	0.00	0.00
14	Other Comprehensive Income	414.49	359.15	401.31	1,159.71	1503.27	1979.04
	A(i)Items that will not be reclassified to profit or loss
		0.00	0.00	0.00	0.00	0.00	0.00
	(ii) Income tax relating to items that will not be
	reclassified to profit or loss B (i) Items that will be reclassified to profit or loss	0.00	0.00	0.00	0.00	0.00	0.00
		111.57	121.30	174.85	147.51	197.17	121.70
	(ii) Income tax relating to items that will be reclassified
	to profit or loss	0.00	0.00	0.00	0.00	0.00	0.00
15	Total Comprehensive Income for the period (XIII+XIV) (Comprising Profit (Loss) and Other
	Comprehensive Income for the period)
		526.06	480.45	576.16	1,307.22	1700.44	2100.74
16	Paid up Share Capital of the Company (Face Value 1/-)	9,400.00	9,400.00	8,299.53	9,400.00	8299.53	8,624.53
17	Reserves excluding revaluation reserves						13,597.63
18	Earnings per equity share (for continuing operation):
	$(1)$ Basic	0.06	0.06	0.07	0.14	0.21	0.26
19	(2) Diluted Earnings per equity share (for discontinued operation):	0.06	0.06	0.06	0.14	0.19	0.24
	$(1)$ Basic	0.00	0.00	0.00	0.00	0.00	0.00
	(2) Diluted	0.00	0.00	0.00	0.00	0.00	0.00
20	Earnings per equity share (for discontinued & continuing operations)
	$(1)$ Basic	0.06	0.06	0.07	0.14	0.20	0.26
	(2) Diluted	0.06	0.06	0.06	0.14	0.19	0.24

Place: Indore

Date: 13/02/2023

HCQM

For, Syncom Formulations (India) Limited

SYNCOM FORMULATIONS (INDIA) LIMITED

Regd.Off :- 7, Niraj Industrial Estate, Off Mahakali Caves Road, Andheri (E) Mumbai-400093

Works:- 256-257, Sector - 1, Pithampur, Dist: Dhar-454775

E Mail:- finance@sfil.in, Website:- www.sfil.in, CIN :- L24239MH1988PLC047759

CONSOLIDATED UNAUDITED FINANCIAL RESULTS FOR THE QUARTER/NINE MONTHS ENDED 31ST DECEMBER . 2022

							Rs. In Lacs
S. No.	Particulars		Quarter Ended			Nine months ended
		31-12-2022	30-09-2022	31-12-2021	31-12-2022	31-12-2021	31-03-2022
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
$\mathbf{1}$	Segment Revenue
	a) Pharmaceuticals Drugs & Formulations	4,615.43	5,644.39	5.520.24	15105.62	16,006.79	21954.68
	b) Trading of Commodities	1.237.55	1.43	353.53	1749.39	570.84	942.33
	c) Renting of Property	83.16	90.51	72.37	255.47	194.68	268.55
	Total Segment Revenue	5,936.14	5,736.33	5,946.14	17110.48	16772.31	23165.56
	Less: Inter Segment Revenue						0.00
	Total Income	5,936.14	5,736.33	5,946.14	17110.48	16,772.31	23165.56
$\overline{2}$	Segment Results Profit(+)/Loss(-) before tax
	and interest from each segment
	a) Pharmaceuticals Drugs & Formulations	583.92	507.18	535.31	1538.04	1,869.98	2427.82
	b) Trading of Commodities	1.16	0.32	6.60	19.18	27.55	56.74
	c) Renting of Property	83.16	90.51	72.37	255.47	194.68	268.55
	Total Profit before tax and Interest	668.24	598.01	614.28	1812.69	2092.21	2753.11
	Less: i) Interest	71.70	61.76	15.39	183.83	46.27	135.52
	ii) Other Un-allocable Expenditure				0.00	3.48	0.00
	Profit before tax	596.54	536.25	598.89	1628.86	2,049.42	2617.59
3	(Segment Asset-Segment Liabilities)
	Segment Asset
	a) Pharmaceuticals Drugs & Formulations	33, 163. 26	32,914.59	28,864.08	33163.26	28,864.08	25600.88
	b) Trading of Commodities	$\epsilon =$		157.82	0.00	157.82	483.73
	c) Renting of Property	4,733.45	4,753.65	4,713.34	4733.45	4,713.34	4739.22
	Total Segment Asset	37,896.71	37,668.24	33,735.24	37896.71	33,735.24	30823.83
	Un-allocable Assets		ä,			s.	0.00
	Net Segment Asset	37,896.71	37,668.24	33,735.24	37896.71	33,735.24	30823.83
	Segment Liabilities
	a) Pharmaceuticals Drugs & Formulations	13032.44	13,330.61	7,721.12	13032.44	7.721.12	8412.34
	b) Trading of Commodities	0.00		93.42	0.00	93.42
	c) Renting of Property	157.79	157.74	4,713.34	157.79	4,713.34	42.68 146.65
	Total Segment Liabilities	13190.23	13,488.35	12,527.88	13190.23	12,527.88	8601.67
	Un-allocable Liabilities						0.00
	Net Segment Liabilities	13190.23	13,488.35	12,527.88	13190.23
Jotge:						12,527.88	8601.67

SYNCON

1 The above Consolidated results were reviewed by the Audit Committee and approved by the Board at its meeting held on 13/02/2023.

2 These above Consolidated results have been prepared in compliance with the Indian Accounting Standard (referred to as "Ind AS") as notified prescribed under Section 133 of the Companies Act, 2013 read with Companies (Indian Accounting Standards) Rules 2015 as amended from time to time.

• 3 The company is operating in 3 segments i.e. (a) Pharmaceuticals Drugs & Formulations (b) Trading of Commodities (c) Renting of Property, particulars of segment wise results are given as required.
• 4 As required under Regulation 33 of SEBI (LODR) Regulations, 2015 the limited review by the Statutory Auditors have been completed for the quarter ended on 31st December, 2022. The report does not have any impact on the above results and notes which needs explanation.
• 5 Syncom Formulations (India) Limited is Parent entity and it has 3 (three) Wholly Owned Subsidiaries namely Synmex Pharma Pvt. Ltd. and Sante Biotech Pvt. Ltd. incorporated on 21st July, 2022 and Vincit Biotech International Pvt. Ltd. incorporated on 25th July, 2022. These companies have not commenced business till the reporting date. The
  Company has presented Standalone & Consolidated Financ and preliminary expenses incurred for there incorporation. Apart from this, there are no Associate or Joint Venture.
• 6 The company has generated Rs. 1035.76 Lakhs being the upfront amount and Rs. 2995.74 Lakhs by conversion of 15,93,47,820 warrants to 15,93,47,820 equity shares of Rs. 1/- each issued at a premium of Rs. 1.53 per share aggregating Rs. 4031.50 Lakhs. Out of which the company has already utilized the amount of Rs. 1002.50 Lakhs being the work is completed and capitalized as well as Rs. 2048.50 Lakhs is utilized towards the continuing ongoing capital work in progress, total Rs.3051.00 Lakhs. Remaining unutilized amount of Rs. 980.50 Lakhs will be used in the subsequent period. There is no deviation in the project till 31st December, 2022 and necessary report towards as required under regulation 32 being filed to the BSE Ltd. and NSE Ltd. separately.

7 Government of India's Code for Social Security 2020(the 'Code') received assent from the President in September 2020. However, the date from when the Code will become applicable and the Rules have not yet been notified. Company will assess the impact of the Code and account for the same once the effective date and rules are notified.

Place: Indore Date: 13/02/2023

For, Syncom Formulations (India) Limited

ATU FOR Kedarmal Shankarlal Bankda Charman & Wholetime Director Σ Ō DIN: 00023050 ۵. $*$ 03